Polaryx Therapeutics, Inc. - 8-K Filing

Polaryx Therapeutics appoints Will Charlton, M.D., as Chief Medical Officer effective September 1, 2026 (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)

SEC EDGAR ·

Tickers: $PLYX

Read the full article at SEC EDGAR

More Regulatory news